ALLIANCE FOR HUMAN RESEARCH PROTECTION Promoting Openness, Full
Disclosure, and Accountability http://www.ahrp.org and
"The current issue of The Lancet, includes a meta-analysis comparing
the efficacy of old and new neuroleptics--a.k.a. first generation
antipsychotics and 'atypical' second generation antipsychotics. The
findings corroborate the fact that the new drugs are no better than
the old antipsychotics.
A Commentary in the same issue, "The Spurious Advance of Antipsychotic
Drug Therapy," by Dr. Peter Tyrer, professor of community psychiatry,
Imperial College, London, and Tim Kendal, MD, co-director of the
Royal College of Psychiatrists' national collaborating centre for
mental health, leads one to conclude that doctors have been 'conned'
by drug manufacturers:
"The new generation of drugs, known as atypicals, were heralded as
safer and more effective than the earlier antipsychotics, and for
the past 20 years doctors have been bbeguiledb into thinking they
'The spurious invention of the atypicals can now be regarded as
invention only, cleverly manipulated by the drug industry for
marketing purposes and only now being exposed.' (Source: Lancet,
2009; 373: 4-5; 31-41).
We would beg to disagree: given the active (duplicitous) role of
prominent academic psychiatrists, as well the major professional
associations in psychiatrybthe American Psychiatric Association,
the American College of Neuropsychopharmacology, the American Academy
of Child and Adolescent Psychiatry, et al in promoting the second
generation antipsychotics, it is unfair to lay blame entirely on
the pharmaceutical industry...."
Continue reading here.